Prognostic model predicts survival in bladder cancer patients using aging-related genes, highlighting immune microenvironment implications.
Key Points
The ARG-based risk score significantly predicts clinical prognosis in bladder cancer patients, correlating with immune microenvironment characteristics.
In the TCGA cohort, AUC values from 0.772 to 0.794 across 1-5 years indicate the model's robust predictive performance.
Patients with low-risk scores exhibited better overall survival (P < .0001), emphasizing the model's capability for stratifying risk.
Cross-validation with the GSE32894 dataset supports the ARG signature's reliability in clinical settings for bladder cancer.